Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine

De Whalley, P; Snape, MD; Kelly, D; Banner, C; Lewis, S; Diggle, L; John, T; Yu, L; Omar, O; Borkowski, A; Pollard, A

Journal article

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine

Abstract:: Background: Bactericidal antibody induced by immunization of infants with serogroup C Neisseria meningitidis (MenC) vaccines wanes rapidly during childhood. Adolescents are at particular risk from meningococcal disease, therefore they might benefit from a booster dose of vaccine. The duration of serologic response to such a booster in adolescents is unknown. Methods: In a previous study, English schoolchildren, aged 9 to 12 years, who had received a monovalent MenC glycoconjugate vaccine in 1999-2000, were given either a plain polysaccharide vaccine (MenC-PS group, n = 150) or a glycoconjugate vaccine (MenC-CRM group, n = 95) at 13 to 15 years of age. In this follow-up study, serum bactericidal antibody titers and specific immunoglobulin G concentrations were assessed 1 year later. Results were compared with unboosted controls of similar age (control group, n = 298). Results: Compliance with study protocol was achieved for 146 of the MenC-PS group, 92 of the MenC-CRM group, and 293 of the control group. Compared with the control group, both the MenC-PS and MenC-CRM groups had a significantly higher (P < 0.0001) geometric mean serum bactericidal antibody titers 1 year after the booster dose (geometric mean titers for MenC-PS group 3388 [95% confidence interval {CI}: 2460-4665]; MenC-CRM group 4417 [95% CI: 2951-6609]; control group 316 [95% CI: 252-396]). Specific immunoglobulin G concentration also rose and remained elevated 1 year after the booster. Conclusions: A booster dose of MenC vaccine given to adolescents produced a marked rise in bactericidal antibody, which remained elevated 1 year later. Introduction of an adolescent booster of MenC vaccine might provide enhanced long-term population control of the disease. © 2011 by Lippincott Williams and Wilkins.

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

De Whalley, P., Snape, M. D., Kelly, D., Banner, C., Lewis, S., Diggle, L., John, T., Yu, L., Omar, O., Borkowski, A., & Pollard, A. (2011). Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine. Pediatric Infectious Disease Journal, 30(11).

MLA Style

De Whalley, P, et al. “Persistence of Serum Bactericidal Antibody One Year after a Booster Dose of Either a Glycoconjugate or a Plain Polysaccharide Vaccine against Serogroup C Neisseria Meningitidis given to Adolescents Previously Immunized with a Glycoconjugate Vaccine.” Pediatric Infectious Disease Journal, vol. 30, no. 11, 2011.

Chicago Style

De Whalley, P, MD Snape, D Kelly, et al. 2011. “Persistence of Serum Bactericidal Antibody One Year after a Booster Dose of Either a Glycoconjugate or a Plain Polysaccharide Vaccine against Serogroup C Neisseria Meningitidis given to Adolescents Previously Immunized with a Glycoconjugate Vaccine.” Pediatric Infectious Disease Journal 30 (11).
Print